A biopsychosocial model of MDMA-assisted therapy in application: Dyadic One Session Treatment for specific phobia

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Anxiety, stress, and fear-based disorders involve maladapted neural circuits for fear, threat, and reward processing.
• 3,4-methylenedioxymethamphetamine (MDMA) has shown efficacy in treating posttraumatic stress disorder (PTSD), potentially via its effects on these neural circuits.
• No studies have investigated MDMA's therapeutic potential for specific phobias.

Purpose of the Study:

• To propose a naturalistic biopsychosocial model of MDMA-assisted therapy (MDMA-AT) for transdiagnostic treatment of fear-based disorders.
• To adapt this model into a novel MDMA-assisted Dyadic One Session Treatment (DOST) for spider phobia.
• To explore MDMA's potential to normalize approach/avoidance behaviors and neural circuit function in specific phobias.

Main Methods:

• The proposed model integrates MDMA's neurobiological mechanisms with Emotional Processing Theory (EPT), inhibitory learning, and cognitive behavioral interpersonal theory (CBIT).
• A novel MDMA-assisted Dyadic One Session Treatment (DOST) model is proposed for spider phobia, a common animal phobia.
• The model leverages MDMA's prosocial effects to enhance emotional processing and inhibitory learning during exposure therapy.

Main Results:

• Hypothesized that MDMA's effects can promote enhanced emotional processing and inhibitory learning of phobic stimuli.
• Anticipated that this will lead to the formation of more adaptive associations during exposure exercises.
• Expected outcomes include increased approach behavior and reduced spider phobia symptomatology.

Conclusions:

• MDMA-assisted therapy holds potential for treating specific phobias by normalizing neural circuit function and behavioral responses.
• The proposed MDMA-AT and DOST models provide a framework for integrating MDMA with exposure therapies.
• This approach may advance the treatment of fear-based mental health conditions by capitalizing on MDMA's pharmacological effects.